CALGB 9710 Protokolü

İndüksiyon Tedavisi

    All trans retinoic acid (ATRA) 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
    Cytarabine (Ara-C) 200 mg/m2/d civi d3-9
    Daunorubicin 50 mg/m2/d iv d3-6

Konsolidasyon Tedavisi

    Arsenic Trioxide (As2O3) 0.15 mg/kg/d x 5d/week for 5 wks x 2 Kürs (Kür 2 starts after 2 wks rest)
    followed by
    All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1-7 x 2 Kürs
    Daunorubicin 50 mg/m2/d iv d1-3 x 2 Kür

İdame Tedavisi

    All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1-7 qow x 1 year
    6-Mercaptopurine (6-MP) 60 mg/m2 po qd x 1 year
    Methotrexate (MTX) 20 mg/m2 po qw x 1 year.


EAPLG Protokolü

Yaş < 60 and WBC < 10,000/uL 

İndüksiyon Tedavisi

    All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
    Cytarabine (Ara-C) 200 mg/m2/d civi d3-9
    Daunorubicin 60 mg/m2/d iv d3-5

Konsolidasyon Tedavisi

    Kür 1
    Cytarabine (Ara-C) 200 mg/m2/d civi d1-7
    Daunorubicin 60 mg/m2/d iv d1-3

    Kür 2
    Cytarabine (Ara-C) 1000 mg/m2 iv q12h x 8 doses
    Daunorubicin 45 mg/m2/d iv d1-3

İdame Tedavisi

    All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1-15 q3m x 2 year
    6-Mercaptopurine (6-MP) 90 mg/m2 po qd x 2 year
    Methotrexate (MTX) 15 mg/m2 po qw x 2 year


Yaş < 60 and WBC > 10,000/uL

İndüksiyon Tedavisi

    All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
    Cytarabine (Ara-C) 200 mg/m2/d civi d3-9
    Daunorubicin 60 mg/m2/d iv d3-5

Konsolidasyon Tedavisi

    Kür 1
    Cytarabine (Ara-C) 200 mg/m2/d civi d1-7
    Daunorubicin 60 mg/m2/d iv d1-3
    Intrathecal Cytarabine (Ara-C) 50 mg and Methotrexate (MTX) 15 mg x 3
    

    Kür 2
    Cytarabine (Ara-C) 2000 mg/m2 iv q12h x 10 doses
    Daunorubicin 45 mg/m2/d iv d1-3
    Intrathecal Cytarabine (Ara-C) 50 mg and Methotrexate (MTX) 15 mg x 2

İdame Tedavisi

    All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1-15 q3m x 2 year
    6-Mercaptopurine (6-MP) 90 mg/m2 po qd x 2 year
    Methotrexate (MTX) 15 mg/m2 po qw x 2 year


Yaş > 60 and WBC < 10,000/uL 

İndüksiyon Tedavisi

    All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
    Daunorubicin 60 mg/m2/d iv d3-5

Konsolidasyon Tedavisi

    Kür 1
    Daunorubicin 60 mg/m2/d iv d1-3

    Kür 2
    Daunorubicin 45 mg/m2/d iv d1-3

İdame Tedavisi

    All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1-15 q3m x 2 year
    6-Mercaptopurine (6-MP) 90 mg/m2 po qd x 2 year
    Methotrexate (MTX) 15 mg/m2 po qw x 2 year
 

Yaş > 60 and WBC > 10,000/uL 

İndüksiyon Tedavisi

    All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1 till hematologic CR
    Cytarabine (Ara-C) 200 mg/m2/d civi d3-9
    Daunorubicin 60 mg/m2/d iv d3-5

Konsolidasyon Tedavisi

    Kür 1
    Cytarabine (Ara-C) 200 mg/m2/d civi d1-7
    Daunorubicin 60 mg/m2/d iv d1-3
    Intrathecal Cytarabine (Ara-C) 50 mg and Methotrexate (MTX) 15 mg x 3
    
    Kür 2
    Cytarabine (Ara-C) 1000 mg/m2 iv q12h x 8 doses
    Daunorubicin 45 mg/m2/d iv d1-3
    Intrathecal Cytarabine (Ara-C) 50 mg and Methotrexate (MTX) 15 mg x2

İdame Tedavisi

    All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1-15 q3m x 2 year
    6-Mercaptopurine (6-MP) 90 mg/m2 po qd x 2 year
    Methotrexate (MTX) 15 mg/m2 po qw x 2 year

 
ATRA + Arsenic Trioxide

All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses d1 till CR
Arsenic Trioxide (As2O3) 0.15 mg/kg/d iv over 1 h d10 till CR
If WBC > 10 x 109/L, add
Gemtuzumab 9 mg/m2 iv d1 and/or
Idarubicin 12 mg/m2/d iv d1-4
Once CR obtained, change to
All trans retinoic avid (ATRA) 45 mg/m2 po qd in 2 divided doses 2 wks on and 2 wks off x 28 wks
Arsenic Trioxide (As2O3) 0.15 mg/kg/d iv d1-5 qw 4 wks on and 4 wks off x 28 wks